Voleon Capital Management LP Reduces Stock Position in Boston Scientific Corporation $BSX

Key Points

• Voleon Capital Management LP reduced its stake in Boston Scientific by 35.1%, selling 19,632 shares to hold a total of 36,360 shares, valued at $3.67 million.
• Several institutional investors increased their stakes in Boston Scientific, including Vanguard Group Inc. and UBS AM, which now hold 134.6 million shares and 10.8 million shares respectively.
• Boston Scientific reported a strong quarterly performance with $5.06 billion in revenue, surpassing expectations, and set Q3 2025 earnings guidance of $0.700-$0.720 EPS.

Voleon Capital Management LP reduced its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 35.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 36,360 shares of the medical equipment provider's stock after selling 19,632 shares during the quarter. Voleon Capital Management LP's holdings in Boston Scientific were worth $3,668,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in BSX. GAMMA Investing LLC raised its stake in Boston Scientific by 11,720.3% during the 1st quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider's stock worth $260,057,000 after buying an additional 2,556,078 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Boston Scientific by 18.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,839,362 shares of the medical equipment provider's stock worth $968,172,000 after buying an additional 1,709,461 shares during the period. Vanguard Group Inc. increased its holdings in Boston Scientific by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock worth $13,577,311,000 after purchasing an additional 1,697,945 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Boston Scientific by 18.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock worth $1,070,387,000 after purchasing an additional 1,664,108 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in Boston Scientific by 161.9% during the 1st quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider's stock worth $250,757,000 after purchasing an additional 1,536,663 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Stock Performance

Shares of BSX stock traded down $1.63 during trading on Friday, hitting $102.71. The company's stock had a trading volume of 10,541,837 shares, compared to its average volume of 6,118,901. The company has a market cap of $152.19 billion, a PE ratio of 61.14, a P/E/G ratio of 2.51 and a beta of 0.65. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The business has a fifty day moving average of $104.86 and a 200-day moving average of $102.26. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same period in the prior year, the company posted $0.62 earnings per share. Boston Scientific's quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of the firm's stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director directly owned 2,081 shares of the company's stock, valued at $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company's stock, valued at $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 174,214 shares of company stock valued at $18,397,457. Corporate insiders own 0.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Needham & Company LLC reissued a "buy" rating and set a $121.00 price objective on shares of Boston Scientific in a report on Thursday. Oppenheimer raised Boston Scientific from a "market perform" rating to an "outperform" rating and boosted their price objective for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Leerink Partners assumed coverage on Boston Scientific in a report on Monday, June 16th. They set an "outperform" rating and a $118.00 price objective for the company. Jefferies Financial Group reissued a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Finally, Truist Financial boosted their price objective on Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a report on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $118.04.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.